MT-228

• Description :

  MT-228 (BPN-0026709) is a selective and blood-brain barrier permeable non-muscle myosin II inhibitor. MT-228 markedly improves tolerability by selectively targeting NMIIB (KI = 1.5 μM) over CMII (KI = 17 μM), and the sequence of SmMll MD is 83.6% identical to that of NMllB. MT-228 shows long-lasting efficacy in animal models of stimulant use disorder[1].

• Product Name Alternative :

  BPN-0026709

• UNSPSC :

  12352005

• Target :

  Myosin

• Related Pathways :

  Cytoskeleton

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Purity :

  99.9

• Smiles :

  O=C1[C@@]2(O)C(N(C3=CC(OC)=NC=C3)CC2)=NC4=C1C=C(C)C(C)=C4

• Molecular Formula :

  C19H19N3O3

• Molecular Weight :

  337.37

• References & Citations :

  [1]Radnai L, et al. Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic Potential. bioRxiv [Preprint]. 2024 Oct 12:2024.10.07.617018.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2404652-24-8]